| Literature DB >> 33017350 |
Chen Zheng1, Xiao Yu Tian2, Feng Hua Sun3, Wendy Yajun Huang4, Sinead Sheridan1, Yalan Wu2, Stephen Heung-Sang Wong1.
Abstract
PURPOSE: Sitting time (ST) is a serious global health issue and positively associated with cardiometabolic disease. The present study investigated associations between objectively measured ST, sedentary patterns, and cardiometabolic biomarkers in physically active young males.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33017350 PMCID: PMC7969161 DOI: 10.1249/MSS.0000000000002528
Source DB: PubMed Journal: Med Sci Sports Exerc ISSN: 0195-9131
List of primers.
| Gene | Forward | Reverse |
|---|---|---|
| E-selectin | TGTGGGTCTGGGTAGGAACC | AGCTGTGTAGCATAGGGCAAG |
| P-selectin | ACTGCCAGAATCGCTACACAG | CACCCATGTCCATGTCTTATTGT |
| ICAM-1 | TTGGGCATAGAGACCCCGTT | GCACATTGCTCAGTTCATACACC |
| CD44 | CTGCCGCTTTGCAGGTGTA | CATTGTGGGCAAGGTGCTATT |
| PSGL-1 | CCTGAGTCTACCACTGTGGAG | GCTGCTGAATCCGTGGACA |
| ESL-1 | CCAAGATGACGGCCATCATTT | AGCCGAATACTGCCACATTTC |
| IL-6 | CCTGAACCTTCCAAAGATGGC | TTCACCAGGCAAGTCTCCTCA |
| IL-1β | AGCTACGAATCTCCGACCAC | CGTTATCCCATGTGTCGAAGAA |
| TNF-α | CCTCTCTCTAATCAGCCCTCTG | GAGGACCTGGGAGTAGATGAG |
| GAPDH | CCACTCCTCCACCTTTGAC | ACCCTGTTGCTGTAGCCA |
PSGL-1, P-selectin glycoprotein ligand-1; ESL-1, E-selectin ligand 1; TNF-α, tumor necrosis factor α; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Participants’ characteristics (n = 94).
| Mean ± SD or % | |
|---|---|
| Individual variables | |
| Age (yr) | 21.7 ± 3.8 |
| Weight (kg) | 62.2 ± 6.6 |
| Height (cm) | 171.6 ± 6.3 |
| BMI (kg·m−2) | 21.1 ± 1.8 |
| Waist circumference (cm) | 74.4 ± 5.3 |
| Diastolic blood pressure (mm Hg) | 71.1 ± 7.2 |
| Systolic blood pressure (mm Hg) | 109.1 ± 8.5 |
| Family history of diabetes (%) | 22.7 |
| Family history of CVD (%) | 36.1 |
| Accelerometer-derived variables | |
| Wear time (h·d−1) | 24.0 ± 0.1 |
| ST (h·d−1) | 10.8 ± 1.6 |
| Prolonged sedentary bouts (h·d−1) | 6.1 ± 1.9 |
| Number of sedentary breaks (per day) | 47.5 ± 13.0 |
| MVPA (h·d−1) | 1.1 ± 0.5 |
| Biomarkers | |
| TC (mg·dL−1) | 167.7 ± 26.5 |
| TG (mg·dL−1) | 115.8 ± 13.7 |
| LDL-C (mg·dL−1) | 92.8 ± 25.8 |
| HDL-C (mg·dL−1) | 51.7 ± 5.2 |
| Plasma glucose (mmol·L−1) | 4.8 ± 0.3 |
| Insulin (pmol·L−1) | 37.6 ± 17.1 |
| C-peptide (pmol·L−1) | 5.4 ± 1.7 |
| HOMA-IR | 1.2 ± 0.6 |
| Leptin (ng·mL−1) | 1.5 ± 1.4 |
| Resistin (ng·mL−1) | 1.5 ± 0.9 |
| Adiponectin (μg·mL−1) | 17.5 ± 10.1 |
| CRP (μg·mL−1) | 1.3 ± 1.1 |
| E-selectin (ng·mL−1) | 26.7 ± 14.3 |
| P-selectin (ng·mL−1) | 37.7 ± 24.6 |
| VCAM-1 (μg·mL−1) | 1.9 ± 1.2 |
| ICAM-1 (ng·mL−1) | 78.5 ± 41.9 |
Associations of sedentary patterns with cadiometabolic biomarkers (n = 94).
| Biomarkers | Model | Total ST (h·d−1) | Prolonged Sedentary Bouts (h·d−1) | Sedentary Breaks ( |
|---|---|---|---|---|
| TC (mg·dL−1) | 1 | 0.151 (−3.141 to 3.443) | −1.100 (−3.823 to 1.622) | 0.057 (−0.356 to 0.469) |
| 2 | −0.360 (−4.087 to 3.367) | −1.407 (−4.225 to 1.411) | 0.075 (−0.340 to 0.489) | |
| TG (mg·dL−1) | 1 | 1.814 (0.107 to 3.520)* | 0.141 (−1.307 to 1.589) | 0.184 (−0.023 to 0.392) |
| 2 | 2.048 (0.116 to 3.981)* | 0.039 (−1.463 to 1.541) | 0.178 (−0.031 to 0.387) | |
| LDL-C (mg·dL−1) | 1 | −0.413 (−3.627 to 2.801) | −0.839 (−3.502 to 1.824) | 0.033 (−0.369 to 0.435) |
| 2 | −0.705 (−4.348 to 2.939) | −0.974 (−3.737 to 1.789) | 0.045 (−0.360 to 0.450) | |
| HDL-C (mg·dL−1) | 1 | 0.201 (−0.466 to 0.869) | −0.290 (−0.841 to 0.262) | −0.013 (−0.097 to 0.070) |
| 2 | −0.065 (−0.813 to 0.684) | −0.441 (−1.003 to 0.121) | −0.006 (−0.089 to 0.077) | |
| Plasma glucose (mmol·L−1) | 1 | 0.004 (−0.031 to 0.038) | 0.014 (−0.015 to 0.043) | 0.001 (−0.003 to 0.005) |
| 2 | −0.009 (−0.048 to 0.030) | 0.009 (−0.020 to 0.039) | 0.002 (−0.003 to 0.006) | |
| Insulin (pmol·L−1) | 1 | 2.117 (0.024 to 4.210)* | 1.374 (−0.389 to 3.137) | 0.211 (−0.047 to 0.470) |
| 2 | 1.398 (−0.963 to 3.758) | 0.946 (−0.860 to 2.752) | 0.233 (−0.025 to 0.491) | |
| C-peptide (pmol·L−1) | 1 | 0.100 (−0.109 to 0.310) | −0.007 (−0.183 to 0.169) | 0.022 (−0.003 to 0.048) |
| 2 | 0.091 (−0.147 to 0.330) | −0.024 (−0.206 to 0.159) | 0.023 (−0.004 to 0.049) | |
| HOMA-IR | 1 | 0.071 (0.003 to 0.138)* | 0.049 (−0.008 to 0.105) | 0.007 (−0.002 to 0.015) |
| 2 | 0.047 (−0.029 to 0.122) | 0.035 (−0.023 to 0.093) | 0.007 (−0.001 to 0.016) | |
| Leptin (ng·mL−1) | 1 | 0.057 (−0.040 to 0.155) | 0.086 (0.001 to 0.171)* | −0.017 (−0.029 to −0.004)** |
| 2 | −0.001 (−0.108 to 0.107) | 0.060 (−0.024 to 0.144) | −0.012 (−0.026 to 0.001) | |
| Resistin (ng·mL−1) | 1 | −0.001 (−0.112 to 0.110) | 0.011 (−0.081 to 0.103) | 0.006 (−0.008 to 0.020) |
| 2 | 0.069 (−0.055 to 0.194) | 0.040 (−0.054 to 0.135) | 0.004 (−0.010 to 0.018) | |
| Adiponectin (μg·mL−1) | 1 | −0.443 (−1.621 to 0.734) | −0.480 (−1.451 to 0.490) | 0.007 (−0.142 to 0.156) |
| 2 | −0.812 (−2.157 to 0.533) | −0.616 (−1.626 to 0.394) | 0.016 (−0.134 to 0.165) | |
| CRP (μg·mL−1) | 1 | −0.043 (−0.148 to 0.063) | −0.011 (−0.103 to 0.080) | −0.016 (−0.029 to −0.004)** |
| 2 | −0.054 (−0.170 to 0.062) | −0.014 (−0.110 to 0.081) | −0.016 (−0.029 to −0.004)** | |
| E-selectin (ng·mL−1) | 1 | 2.052 (0.297 to 3.807)* | 1.623 (0.156 to 3.090)* | −0.032 (−0.257 to 0.193) |
| 2 | 1.961 (−0.059 to 3.981) | 1.474 (−0.038 to 2.985) | −0.028 (−0.253 to 0.197) | |
| P-selectin (ng·mL−1) | 1 | 2.928 (−0.068 to 5.923) | 2.519 (0.026 to 5.012)* | 0.066 (−0.316 to 0.448) |
| 2 | 3.239 (−0.208 to 6.685) | 2.471 (−0.106 to 5.047) | 0.064 (−0.319 to 0.447) | |
| VCAM-1 (μg·mL−1) | 1 | −0.003 (−0.069 to 0.064) | 0.022 (−0.035 to 0.079) | 0.001 (−0.008 to 0.010) |
| 2 | 0.025 (−0.048 to 0.098) | 0.032 (−0.025 to 0.090) | 0.000 (−0.008 to 0.009) | |
| ICAM-1 (ng·mL−1) | 1 | 0.165 (−5.044 to 5.375) | 2.517 (−1.795 to 6.829) | −0.162 (−0.824 to 0.500) |
| 2 | 3.550 (−2.287 to 9.387) | 3.828 (−0.503 to 8.160) | −0.214 (−0.862 to 0.434) |
Model 1: adjusting for age, BMI, activPAL wear time, family history of diabetes, family history of CVD, and ST (sedentary breaks only). Model 2: adjusting for the above covariates and MVPA.
*P < 0.05.
**P < 0.01.
Associations of total ST with mRNA expression levels (n = 75).
| mRNA Expression Levels | B (95% CI) | |
|---|---|---|
| Model 1 | Model 2 | |
| Cadiometabolic-related marker | ||
| E-selectin | 0.0002 (0.0001 to 0.0003)** | 0.0002 (0.0000 to 0.0003)* |
| P-selectin | 0.0034 (−0.0056 to 0.0124) | 0.0026 (−0.0076 to 0.0128) |
| ICAM-1 | −0.0000 (−0.0018 to 0.0018) | 0.0005 (−0.0015 to 0.0025) |
| IL-6 | 0.0001 (−0.0000 to 0.0002) | 0.0001 (−0.0000 to 0.0003)*** |
| IL-1β | 0.0014 (−0.0014 to 0.0042) | 0.0010 (−0.0022 to 0.0041) |
| TNF-α | 0.0002 (−0.0009 to 0.0013) | 0.0002 (−0.0010 to 0.0014) |
| E-selectin ligands | ||
| CD44 | 0.0134 (−0.0151 to 0.0419) | 0.0190 (−0.0131 to 0.0511) |
| PSGL-1 | −0.0033 (−0.0194 to 0.0127) | −0.0042 (−0.0223 to 0.0140) |
| ESL-1 | −0.0020 (−0.0092 to 0.0052) | −0.0030 (−0.0111 to 0.0052) |
Model 1: adjusting for age, BMI, activPAL wear time, family history of diabetes, and family history of CVD. Model 2: adjusting for the above covariates and MVPA. All the mRNA were normalized by the GAPDH expression level.
*P < 0.05.
**P < 0.01.
***P = 0.06.
TNF-α, tumor necrosis factor α; PSGL-1, P-selectin glycoprotein ligand-1; ESL-1, E-selectin ligand 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.